RT Journal Article
SR Electronic
T1 Risk assessment of progression to severe conditions for patients with COVID-19 pneumonia: a single-center retrospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.25.20043166
DO 10.1101/2020.03.25.20043166
A1 Zeng, Lijiao
A1 Li, Jialu
A1 Liao, Mingfeng
A1 Hua, Rui
A1 Huang, Pilai
A1 Zhang, Mingxia
A1 Zhang, Youlong
A1 Shi, Qinlang
A1 Xia, Zhaohua
A1 Ning, Xinzhong
A1 Liu, Dandan
A1 Mo, Jiu
A1 Zhou, Ziyuan
A1 Li, Zigang
A1 Fu, Yu
A1 Liao, Yuhui
A1 Yuan, Jing
A1 Wang, Lifei
A1 He, Qing
A1 Liu, Lei
A1 Qiao, Kun
YR 2021
UL http://medrxiv.org/content/early/2021/08/04/2020.03.25.20043166.abstract
AB Background Management of high mortality risk due to significant progression requires prior assessment of time-to-progression. However, few related methods are available for COVID-19 pneumonia.Methods We retrospectively enrolled 338 adult patients admitted to one hospital between Jan 11, 2020 to Feb 29, 2020. The final follow-up date was March 8, 2020. We compared characteristics between patients with severe and non-severe outcome, and used multivariate survival analyses to assess the risk of progression to severe conditions.Results A total of 76 (31.9%) patients progressed to severe conditions and 3 (0.9%) died. The mean time from hospital admission to severity onset is 3.7 days. Age, body mass index (BMI), fever symptom on admission, co-existing hypertension or diabetes are associated with severe progression. Compared to non-severe group, the severe group already demonstrated, at an early stage, abnormalities in biomarkers indicating organ function, inflammatory responses, blood oxygen and coagulation function. The cohort is characterized with increasing cumulative incidences of severe progression up to 10 days after admission. Competing risks survival model incorporating CT imaging and baseline information showed an improved performance for predicting severity onset (mean time-dependent AUC = 0.880).Conclusions Multiple predisposition factors can be utilized to assess the risk of progression to severe conditions at an early stage. Multivariate survival models can reasonably analyze the progression risk based on early-stage CT images that would otherwise be misjudged by artificial analysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is partially funded by the Shenzhen Science and Technology Innovation Commission, grant No. JSGG20200519160750001, and Sanming Project of Medicine in Shenzhen, grant No. SZSM201812058.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data can be available from corresponding authors upon reasonable request